Health - Gastroenterology latest news
Optimer Pharmaceuticals Completes Enrollment In Second Prulifloxacin Phase 3 Clinical Trial
Optimer Pharmaceuticals, Inc. (Nasdaq:OPTR) announced that the company has completed enrollment in the second of two planned phase 3 clinical trials evaluating the safety and efficacy of Prulifloxacin for the treatment of infectious diarrhea in travelers.
Medicalnewstoday.com Thursday, September 04, 2008
PREVIEW
OF YOUR NEWS WIDGET
INSTALL YOUR WIDGET